Company intelligence / Profile preview

KeyZell

Sevilla, Andalusia, Spainkeyzell.com ↗

Ownership: Private
Development stage: Preclinical

Overview

KeyZell has developed an innovative artificial intelligence system—OPS—for precision oncology that selects optimal personalized treatments using machine learning and biomarker data. Their lead peptide program LZ167 targets cell apoptosis pathways to neutralize tumor cells and prevent metastasis. The company claims preclinical success against glioblastoma and plans Phase I/IIa trials. The OPS system reportedly achieves high efficacy (~89%) in selecting therapies for breast and lung cancers.

Therapeutic areas: Oncology
Modalities: PeptidesArtificial intelligence-based therapySmall molecule
Industry: Biotech

Drug pipeline

1 asset

LZ-167

Unknown

Partnerships

Strategic partner(s) in MexicoUniversity of SevilleHarvard University

Beyond the preview

Go deeper on KeyZell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KeyZell.

Explore the full profile